COVID-19 PocketGuide
Last Updated: Mar 19, 2021
Guidelines Used:
- 2020 IDSA COVID-19, Part 1: Treatment and Management of Patients with COVID-19
- 2020 NIH Coronavirus Disease 2019 (COVID-19) Treatment Guidelines
In the last year, COVID-19 has spread worldwide rapidly, increasing incidence of infections and deaths. The Infectious Diseases Society of America (IDSA) and National Institute of Health (NIH) have spearheaded efforts to provide updated evidence-based guidelines to support treatment and management of patients with COVID-19 with researchers all over the world.
Based on a request, here is a summary of coronavirus-19 disease (COVID-19) guidelines and clinical trials **as of March 19, 2021**. Evidence is rapidly changing; please be diligent in viewing the latest evidence-based data.
COVID-19 Compiled Clinical Trials with their Therapies (as of March 19, 2021)
|
Therapy |
MOA |
Associated Clinical Trials |
|
Hydroxychloroquine |
Antimalarial |
Barnabas et al, 8 December 2020 Mitjà et al. 24 November 2020 Self et al, 9 November 2020 Rajasingham et al, 17 October 2020 RECOVERY Collab group, 8 October 2020 Abella et al, 30 September 2020 RECOVERY, 5 June 2020 Boulware et al, 3 June 2020 |
|
Hydroxychloroquine + azithromycin |
Antimalarial + macrolide antibiotic |
Cavalcanti et al, 23 July 2020 |
|
Azithromycin |
Macrolide antibiotic |
PRINCIPLE, 21 March 2021 Furtado et al, 4 September 2020 |
|
Lopinavir + ritonavir |
HIV type 1 aspartate protease inhibitor + booster |
RECOVERY, 5 October 2020 Horby et al, 29 June 2020 Cao et al, 7 May 2020 |
|
Corticosteroids |
Anti-inflammatory steroid |
RECOVERY Collab Group, 25 February 2021 Tomazini et al, 2 September 2020 Horby et al, 17 July 2020 |
|
Tocilizumab |
Monoclonal antibody that inhibits interleukin (IL-6) |
Soin et al, 4 March 2021 REMAP-CAP Investigators, 25 February 2021 Veiga et al, 20 January 2021 Salama et al. 17 December 2020 Stone et al, 21 October 2020 Hermine et al, 20 October 2020 |
|
Tocilizumab + Remdesivir |
Monoclonal antibody + antiviral |
REMDACTA (Roche), 11 March 2021 |
|
Convalescent plasma |
Recovered COVID-19 patient’s plasma |
Libster et al, 18 February 2021 REMAP-CAP trial 12 January 2021 Simonovich et al, 24 November 2020 Agarwal et al, 22 October 2020 Li et al, 3 June 2020 |
|
Remdesivir |
Broad spectrum antiviral |
Solidarity (WHO), 2 December 2020 Beigel et al, 8 October 2020 Spinner et al, 21 August 2020 Goldman et al, 27 May 2020 Wang et al, 29 April 2020 |
|
Famotidine |
Histamine-2 receptor antagonist |
|
|
Bamlanivimab + etesevimab |
Neutralising IgG1 monoclonal antibody directed against SARS-CoV-2 spike protein |
Gottlieb et al, 21 January 2021 |
|
Bamlanivimab (LY-CoV555) |
*same as above |
BLAZE-2, 21 January 2021 Chen et al, 21 January 2021 ACTIV-3, 26 October 2020 |
|
Baricitinib + Remdesivir |
Janus-associated tyrosine kinase (JAK) 1 and 2 inhibitor (modulates immune response) |
|
|
Ivermectin |
Anti-parasitic |
López-Medina et al, 4 March 2021 |
References
- COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed March 19, 2021.
- IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Infectious Diseases Society of America. Available at https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/#. Accessed March 19, 2021.